Endometriosis, Hypofertility
Conditions
Keywords
endo
Brief summary
Endometriosis is a disease that affects 10-15% of the general population and 50% of infertile women. It is characterized by the presence of endometrial tissue outside the uterine cavity. Endometriosis can lead to infertility by interfering through endocrine and mechanical alterations on the function of the ovaries, fallopian tubes, and uterus. The aim of the study is to define the differential expression of a cluster of RNAs tissue driven for the identification of an RNA profile in saliva, specific for endometriosis. This study focuses on the expression of genes involved in the control and regulation of apoptosis, cell survival, metabolism, cell adhesion and invasion, angiogenesis, inflammation, and estrogen receptor expression levels.
Detailed description
Retrospective selection based on anamnestic criteria of: 50 patients with diagnosed endometriotic adnexal pathology (case, CA), 50 patients with non-endometriotic adnexal pathology (control, CO) and 50 patients with no gynecological pathology, not undergoing surgery (analytical control). The study involves collecting a saliva sample from all patients involved in the study, and performing a biopsy from both patients with endometriotic adnexal pathology (CA) and patients with non-endometriotic adnexal pathology (CO).
Interventions
OTHERObservational study
Observational study in different tissues in identifing new genetic markers related to endometriosis disease
Sponsors
Eurofins Genoma
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Case population (CA), patients with endometriotic adnexal pathology * Control population (CO), patients with non-endometriotic adnexal pathology * Analytical control population (C-), patients with no gynecologic pathology, not undergoing surgery
Exclusion criteria
* Women with ages outside the inclusion range * Pregnant patient * Patient with a personal history of cancer * Patient infected with HIV
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Next Generation Sequencing technical validation | 1 month | Assessing the quality of Next Generation Sequencing via the FASTQC tool. Following benchmarks will be considered: 1.1 Per base sequence quality \[Phred score: positive real number, the higher the better\] 1.2 Total number of sequenced reads \[integer: positiver integer number, the higher the better\] |
| Wet lab kit validation | 1 month | Assessing the quality of the kit by mapping the reads against public miRNA databases. Following benchmark will be considered: Total reads mapped \[integer\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tissue validation | 2 months | Genetic profiling of miRNOME from saliva versus FFPE-tissues |
| Clinical validation | 4 months | Correlation of miRNOME signature in saliva among cases, controls and analytical groups |
| Biomarkers identification | 7 months | Identification of specific signature related to endometriosis, with at least 2 Log2fold change |
Countries
Italy
Outcome results
None listed